XML 31 R25.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Financial Statement Details (Tables)

6 Months Ended

Jun. 30, 2025

Inventory Disclosure [Abstract]

Schedule of Other Current Assets

Other current assets consist of the following (in thousands):


		June 30, 2025				December 31, 2024
Prepaid research and development expenses		$	7,579			$	1,947
Interest and other non-trade receivables			1,351				1,609
Other prepaid expenses			1,733				2,510
Total other current assets		$	10,663			$	6,066

Schedule of Accrued Expenses

Accrued expenses consist of the following (in thousands):


		June 30, 2025				December 31, 2024
Accrued compensation		$	6,549			$	2,832
Accrued research and development expenses			15,448				14,453
Accrued contract termination costs			3,275				2,767
Other accrued expenses			9,827				9,920
Total accrued expenses		$	35,099			$	29,972

Schedule of Liability Related to Sale of Potential Future Royalties

The following is a reconciliation of the changes in our liabilities related to the sales of future royalties for the six months ended June 30, 2025 (in thousands):


		Six Months Ended June 30, 2025
		2012 Purchase and Sale Agreement				2020 Purchase and Sale Agreement				Total
Liabilities related to the sales of future royalties, net – beginning balance		$	7,197			$	84,579			$	91,776
Non-cash royalty revenue			(3,474	)			(18,161	)			(21,635	)
Non-cash interest expense			1,294				9,074				10,368
Amortization of transaction costs			—				64				64
Liabilities related to the sales of future royalties, net – ending balance		$	5,017			$	75,556			$	80,573